The combination of TAS-102 and bevacizumab as the third-line chemotherapy for metastatic colorectal cancer (TAS-CC3 Study).

被引：0
|
作者：
Kosugi, Chihiro
Kamiyama, Hirohiko
Yoshida, Yoichiro
Yoshida, Hiroshi
Ishibashi, Keiichiro
Ihara, Keisuke
Takahashi, Makoto
Kuramochi, Hidekazu
Sonoda, Hiromichi
Yoshimatsu, Kazuhiko
Fukazawa, Atsuko
Matsuda, Akihisa
Yamaguchi, Satoru
Ishida, Hideyuki
Hasegawa, Suguru
Yamada, Takeshi
Narushima, Kazuo
Shuto, Kiyohiko
Sakamoto, Kazuhiro
Koda, Keiji
机构：
[1] Teikyo Univ, Chiba Med Ctr, Ichihara, Chiba, Japan
[2] Juntendo Univ, Sch Med, Dept Coloproctol Surg, Bunkyo Ku, Tokyo, Japan
[3] Fukuoka Univ, Fukuoka, Fukuoka, Japan
[4] Nippon Med Univ, Dept Gastroenterol Surg, Tokyo, Japan
[5] Saitama Med Univ, Saitama, Japan
[6] Dokkyo Univ, Dept Surg Oncol, Sch Med, Mibu, Tochigi, Japan
[7] 3-1-3 Hongo,Bunkyo Ku, Tokyo, Japan
[8] Tokyo Womens Med Univ, Yachiyo Med Ctr, Yachiyoshi Chiba, Japan
[9] Shiga Univ Med Sci, Dept Surg, Otsu, Shiga, Japan
[10] Saiseikai Kurihashi Hosp, Dept Surg, Kuki, Saitama, Japan
[11] Iwata City Hosp, Dept Surg, Iwata, Shizuoka, Japan
[12] Chiba Hokusoh Hosp, Nippon Med Sch, Dept Surg, Chiba, Japan
[13] Fukuoka Univ, Sch Med, Dept Gastroenterol Surg, Fukuoka, Fukuoka, Japan
[14] Nippon Med Sch, Dept Digest Surg, Tokyo, Japan
[15] Teikyo Univ, Chiba Med Ctr, Ichihara, Chiba, Japan
[16] Juntendo Univ, Sch Med, Dept Coloproctol Surg, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.2019.37.4_suppl.614
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
614
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Updated analysis of a phase 2 study of fruquintinib plus trifluridine/tipiracil (TAS-102) as third-line treatment in patients with metastatic colorectal adenocarcinoma
    Xiao, Jianjun
    Long, Jianting
    Huang, Ling
    Li, Yong
    Liu, Jianhua
    Zhang, Haibo
    Xie, Derong
    Wang, Wei
    Weng, Chengyin
    Zhang, Zongcheng
    Chai, Xiaoshu
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 145 - 145
  • [42] Neutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS-102
    Hamauchi, Satoshi
    Yamazaki, Kentaro
    Masuishi, Toshiki
    Kito, Yosuke
    Komori, Azusa
    Tsushima, Takahiro
    Narita, Yukiya
    Todaka, Akiko
    Ishihara, Makoto
    Yokota, Tomoya
    Tanaka, Tsutomu
    Machida, Nozomu
    Kadowaki, Shigenori
    Fukutomi, Akira
    Ura, Takashi
    Onozawa, Yusuke
    Ando, Masashi
    Tajika, Masahiro
    Muro, Kei
    Yasui, Hirofumi
    Mori, Keita
    Taniguchi, Hiroya
    CLINICAL COLORECTAL CANCER, 2017, 16 (01) : 51 - 57
  • [43] Review on TAS-102 development and its use for metastatic colorectal cancer
    Mota, Jose Mauricio
    Fonseca, Leonardo G.
    Braghiroli, Maria Ignez
    Hoff, Paulo M.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 104 : 91 - 97
  • [44] Initial experience of TAS-102 chemotherapy in Australian patients with chemorefractory metastatic colorectal cancer.
    Jalali, Azim
    Wong Hui-Li
    Wong, Rachel
    Lee, Margaret
    Gately, Lucy
    Loft, Matthew
    Shapiro, Jeremy David
    Kosmider, Suzanne
    Tie Jeanne
    Ananda, Sumitra
    Yeung, Justin
    Jennens, Ross
    Lee, Belinda
    McKendrick, Joseph James
    Lim, Lionel
    Khattak, Muhammad Adnan
    Gibbs, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [45] Metastatic descending colon cancer in an elderly man that was controlled with a combination chemotherapy after TAS-102
    Naganuma, Atsushi
    Uehara, Daisuke
    Watanuki, Yuta
    Shiina, Keisuke
    Yoshida, Haruka
    Hayashi, Eri
    Uehara, Sanae
    Hoshino, Takashi
    Kudo, Tomohiro
    Ishihara, Hiroshi
    ANNALS OF ONCOLOGY, 2016, 27
  • [46] Phase II study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer.
    Sun, Yongkun
    Zhang, Jing
    Wu, Guifu
    Zhong, Xiaomin
    Zhang, Wen
    Liang, Ping
    Li, Baoqi
    Cui, Chengxu
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 155 - 155
  • [47] Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
    Johanna C. Bendell
    Lee S. Rosen
    Robert J. Mayer
    Jonathan W. Goldman
    Jeffrey R. Infante
    Fabio Benedetti
    Donghu Lin
    Hirokazu Mizuguchi
    Christopher Zergebel
    Manish R. Patel
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 925 - 932
  • [48] Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
    Bendell, Johanna C.
    Rosen, Lee S.
    Mayer, Robert J.
    Goldman, Jonathan W.
    Infante, Jeffrey R.
    Benedetti, Fabio
    Lin, Donghu
    Mizuguchi, Hirokazu
    Zergebel, Christopher
    Patel, Manish R.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (05) : 925 - 932
  • [49] Phase II study of biweekly TAS-102, irinotecan and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO)
    Boland, Patrick M.
    Mukherjee, Sarbajit
    Imanirad, Iman
    Vijayvergia, Namrata
    Cohen, Seth D.
    Gupta, Medhavi
    Iyer, Renuka V.
    Chatley, Sarah
    Cahill, Beth
    Vadehra, Deepak
    Attwood, Kristopher
    Hochster, Howard S.
    Fountzilas, Christos
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] Muscle quantity and quality in metastatic colorectal cancer patients during third-line therapy with regorafenib or TAS102
    Maddalena, C.
    Ponsiglione, A.
    Camera, L.
    Santarpia, L.
    Pasanisi, F.
    Bruzzese, D.
    D'Amato, M.
    Carlomagno, C.
    ANNALS OF ONCOLOGY, 2022, 33 : S292 - S292
12345